Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- lamivudine
- Liqui-Char with Sorbitol (charcoal / sorbitol)
Interactions between your drugs
lamiVUDine sorbitol
Applies to: lamivudine, Liqui-Char with Sorbitol (charcoal / sorbitol)
GENERALLY AVOID: Sorbitol may decrease the serum concentration of lamivudine. The mechanism of interaction has not been established. In an open-label, randomized sequence, 4-period, crossover study of 16 healthy adult subjects, a single 300 mg dose of lamivudine oral solution was administered alone or in combination with a single 3.2 g, 10.2 g, or 13.4 g dose of sorbitol oral solution. Coadministration of lamivudine with sorbitol resulted in dose-dependent decreases in lamivudine AUC (14%, 32%, and 36%) and Cmax (28%, 52%, and 55%).
MANAGEMENT: When possible, avoid use of lamivudine with products that contain osmotic polyalcohols (e.g., sorbitol) or monosaccharide alcohols (e.g., lactitol, mannitol). If coadministration cannot be avoided, more frequent monitoring of viral load should be considered.
References (4)
- (2001) "Product Information. Epivir (lamivudine)." Glaxo Wellcome
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
- Adkison K, Wolstenholme A, Lou Y, et al. (2017) "Effect of Sorbitol on the Pharmacokinetic Profile of Lamivudine Oral Solution in Adults: An Open-label, Randomized Study." Clin Pharmacol Ther
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Cabenuva
Cabenuva (cabotegravir and rilpivirine) injections are a long-acting HIV treatment used to keep HIV ...
Biktarvy
Biktarvy is a complete HIV-1 treatment in a once-a-day single tablet containing three antiviral ...
Botox
Botox is used to treat chronic migraines, excessive sweating, bladder conditions, eye muscle ...
Descovy
Descovy is used to treat and prevent HIV infection in adults and adolescents. When used for HIV-1 ...
Dovato
Dovato is used to treat HIV-1 infection in adults and children 12 years and older weighing at least ...
Truvada
Truvada is used to prevent HIV (HIV PrEP) or treat HIV-1 infection in combination with other HIV-1 ...
Vemlidy
Vemlidy (tenofovir alafenamide) is an oral, once-daily, antiviral tablet that may be used to treat ...
Atripla
Atripla prevents the human immunodeficiency virus (HIV) from reproducing in your body. Learn about ...
Isentress
Isentress is used to treat HIV, which causes acquired immunodeficiency syndrome (AIDS). Learn about ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.